CPIX director buys via 10b5-1 plan; now holds 44,491 shares

Cumberland Pharmaceuticals (CPIX) director James Jones reported automatic open‑market purchases under a Rule 10b5‑1 trading plan.

Rhea-AI Filing Summary

Cumberland Pharmaceuticals (CPIX) director James Jones reported automatic open‑market purchases under a Rule 10b5‑1 trading plan. The filings show purchases of 13 shares on each trading day from October 1–31, 2025, at prices ranging from $3.14 to $3.63. Following these transactions, Jones beneficially owns 44,491 shares, held direct.

The Rule 10b5‑1 plan was adopted on November 14, 2024. No derivative securities were reported.

Insider Trade Summary

Small Acquisition: 299 shares

Small Acquisition 23 txns

Insider Jones James

Role Director

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock	13	$3.39	$44.07
Small Acquisition	Common Stock	13	$3.29	$42.77
Small Acquisition	Common Stock	13	$3.26	$42.38
Small Acquisition	Common Stock	13	$3.28	$42.64
Small Acquisition	Common Stock	13	$3.49	$45.37
Small Acquisition	Common Stock	13	$3.51	$45.63
Small Acquisition	Common Stock	13	$3.44	$44.72
Small Acquisition	Common Stock	13	$3.62	$47.06
Small Acquisition	Common Stock	13	$3.61	$46.93
Small Acquisition	Common Stock	13	$3.52	$45.76
Small Acquisition	Common Stock	13	$3.48	$45.24
Small Acquisition	Common Stock	13	$3.49	$45.37
Small Acquisition	Common Stock	13	$3.37	$43.81
Small Acquisition	Common Stock	13	$3.35	$43.55
Small Acquisition	Common Stock	13	$3.54	$46.02
Small Acquisition	Common Stock	13	$3.59	$46.67
Small Acquisition	Common Stock	13	$3.56	$46.28
Small Acquisition	Common Stock	13	$3.63	$47.19
Small Acquisition	Common Stock	13	$3.19	$41.47
Small Acquisition	Common Stock	13	$3.14	$40.82
Small Acquisition	Common Stock	13	$3.25	$42.25
Small Acquisition	Common Stock	13	$3.28	$42.64
Small Acquisition	Common Stock	13	$3.31	$43.03

Holdings After Transaction: Common Stock — 44,491 shares (Direct)

Footnotes (1)

1. F1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/03/2025 - 07:58 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones James

(Last) (First) (Middle)

1600 WEST END AVENUE, SUITE 1300

(Street)

NASHVILLE TN 37203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		L	V	13(1)	A	$3.31	44,205	D
Common Stock	10/02/2025		L	V	13(1)	A	$3.28	44,218	D
Common Stock	10/03/2025		L	V	13(1)	A	$3.25	44,231	D
Common Stock	10/06/2025		L	V	13(1)	A	$3.14	44,244	D
Common Stock	10/07/2025		L	V	13(1)	A	$3.19	44,257	D
Common Stock	10/08/2025		L	V	13(1)	A	$3.63	44,270	D
Common Stock	10/09/2025		L	V	13(1)	A	$3.56	44,283	D
Common Stock	10/10/2025		L	V	13(1)	A	$3.59	44,296	D
Common Stock	10/13/2025		L	V	13(1)	A	$3.54	44,309	D
Common Stock	10/14/2025		L	V	13(1)	A	$3.35	44,322	D
Common Stock	10/15/2025		L	V	13(1)	A	$3.37	44,335	D
Common Stock	10/16/2025		L	V	13(1)	A	$3.49	44,348	D
Common Stock	10/17/2025		L	V	13(1)	A	$3.48	44,361	D
Common Stock	10/20/2025		L	V	13(1)	A	$3.52	44,374	D
Common Stock	10/21/2025		L	V	13(1)	A	$3.61	44,387	D
Common Stock	10/22/2025		L	V	13(1)	A	$3.62	44,400	D
Common Stock	10/23/2025		L	V	13(1)	A	$3.44	44,413	D
Common Stock	10/24/2025		L	V	13(1)	A	$3.51	44,426	D
Common Stock	10/27/2025		L	V	13(1)	A	$3.49	44,439	D
Common Stock	10/28/2025		L	V	13(1)	A	$3.28	44,452	D
Common Stock	10/29/2025		L	V	13(1)	A	$3.26	44,465	D
Common Stock	10/30/2025		L	V	13(1)	A	$3.29	44,478	D
Common Stock	10/31/2025		L	V	13(1)	A	$3.39	44,491	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Remarks:

	James Jones by /s/ John Hamm as attorney-in-fact	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.